TABLE OF CONTENTS 
I. CALL TO ORDER 4 
II. PROGRESS REPORT ON ADA PROTOCOL ENTITLED: TREATMENT OF 
SEVERE COMBINED IMMUNODEFICIENCY DISEASE (SCID) DUE TO 
ADENOSINE DEAMINASE (ADA) DEFICIENCY WITH AUTOLOGOUS 
LYMPHOCYTES TRANSDUCED WITH A HUMAN ADA GENE 4 
III. AMENDMENT TO THE POINTS TO CONSIDER IN THE DESIGN AND 
SUBMISSION OF PROTOCOLS FOR THE TRANSFER OF RECOMBINANT 
DNA INTO THE GENOME OF HUMAN SUBJECTS 6 
IV. PROPOSED ADDITION TO APPENDIX D OF THE NIH GUIDELINES 
REGARDING HUMAN GENE TRANSFER PROTOCOLS ENTITLED: (1) 
A PHASE //// TRIAL OF HIGH DOSE CARBOPLATIN AND ETOPOSIDE 
WITH AUTOLOGOUS BONE MARROW SUPPORT FOR TREATMENT OF 
STAGE D NEUROBLASTOMA IN FIRST REMISSION: USE OF MARKER 
GENES TO INVESTIGATE THE BIOLOGY OF MARROW RECONSTITUTION 
AND THE MECHANISM OF RELAPSE; AND (2) A PHASE II TRIAL OF 
HIGH DOSE CARBOPLATIN AND ETOPOSIDE WITH AUTOLOGOUS BONE 
MARROW SUPPORT FOR TREATMENT OF RELAPSE/REFRACTORY 
NEUROBLASTOMA WITHOUT APPARENT BONE MARROW INVOLVEMENT: 
USE OF MARKER GENES TO INVESTIGATE THE BIOLOGY OF MARROW 
RECONSTITUTION AND THE MECHANISM OF RELAPSE 8 
V. PROPOSED ADDITION TO APPENDIX D OF THE NIH GUIDELINES 
REGARDING A HUMAN GENE TRANSFER PROTOCOL ENTITLED: THE 
ADMINISTRATION OF INTERLEUKIN-2 (IL-2), INTERLEUKIN-4 
(IL-4) AND TUMOR INFILTRATING LYMPHOCYTES TO PATIENTS 
WITH MELANOMA 14 
VI. AMENDMENT TO THE POINTS TO CONSIDER IN THE DESIGN AND 
SUBMISSION OF PROTOCOLS FOR THE TRANSFER OF RECOMBINANT 
DNA INTO THE GENOME OF HUMAN SUBJECTS 20 
VII. FUTURE RESPONSIBILITIES OF THE HUMAN GENE THERAPY 
SUBCOMMITTEE 21 
VIII. PROPOSED ADDITION TO APPENDIX D OF THE NIH GUIDELINES 
REGARDING A HUMAN GENE TRANSFER PROTOCOL ENTITLED: 
AUTOLOGOUS TRANSPLANTATION FOR CHRONIC MYELOGENOUS 
LEUKEMIA: RETROVIRAL MARKING TO DISCRIMINATE BETWEEN 
Recombinant DNA Research, Volume 14 
[557] 
